Proffitt & Goodson Inc Summit Therapeutics Inc. Transaction History
Proffitt & Goodson Inc
- $694 Million
- Q3 2025
Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
269Shares Held
92.7MCall Options Held
4.71MPut Options Held
3.17M-
Baker Bros. Advisors LP New York, NY33.7MShares$609 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$206 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$143 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$72.6 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$70.6 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.64B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...